Inflammation 2005 - Seventh World Congress. Rheumatoid arthritis and cell signaling.
Novel targets for antirheumatic therapy were discussed including synoviocyte CD97 and the T-cell co-receptor CTLA-4: an immunoglobulin fusion protein of CTLA-4 (abatacept (Bristol-Myers Squibb Co)) has recently been revealed to be a well-tolerated and effective therapeutic agent for rheumatoid arthritis. Furthermore, cell-signaling molecules were a major topic, and cytoplasmic adaptors of toll-like receptor responses, the kinases JNK and Lyn and the macrophage surface molecule CD200 were considered as potential targets for novel therapies.
Parnham
Michael J
MJ
PLIVA Research Institute Ltd, Prilaz baruna Filipovica 25, Zagreb, Croatia. michael.parnham@pliva.com
D000818:Animals; D015703:Antigens, CD / Q000502:physiology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008562:Membrane Glycoproteins / Q000187:drug effects / Q000502:physiology / Q000627:therapeutic use; D051379:Mice; D043562:Receptors, G-Protein-Coupled; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
C095004:ADGRE5 protein, human; D015703:Antigens, CD; C492346:CD200 receptor, mouse; D015507:Drugs, Investigational; D008562:Membrane Glycoproteins; D043562:Receptors, G-Protein-Coupled